#United States #Los Angeles #Stroke Treatment #Remedy Pharmaceuticals #CIRARA

Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data

Remedy Pharmaceuticals is set to present crucial findings from both the Phase 2 GAMES-RP and Phase 3 CHARM studies at the upcoming International Stroke Conference (ISC) 2025, being held in Los Angeles from February 5 to 7. The focus will be on the efficacy of CIRARA (intravenous glyburide) in treating Large Hemispheric Infarctions (LHI), a severe form of ischemic stroke.

Highlights of the Presentations

At the conference, three specific presentations will be key in illustrating the potential of CIRARA:
1. Meta-Analysis of CIRARA's Efficacy
This segment will take place on February 5 at 8:18 AM and will feature Dr. W. Taylor Kimberly from Massachusetts General Hospital. The meta-analysis combines data from the GAMES-RP and CHARM trials to evaluate CIRARA's effectiveness in treating LHI patients with core lesion volumes of 125 mL or smaller.

2. Endovascular Treatment Outcomes
Also on February 5 at 3:42 PM, Dr. Kevin Sheth will lead a session that examines how CIRARA could potentially enhance recovery outcomes for LHI patients who undergo endovascular therapy. This critical analysis is designed to shed light on the drug's efficacy within the CHARM trial context.

3. Long-Term Outcomes
Dr. Sheth will return on February 6 at 3:42 PM to delve into the long-term outcomes of patients involved in the CHARM trial, focusing on their progress at six and twelve months following treatment.

In addition to these presentations, an invited symposium titled "Bench to Bedside and Beyond" will explore advancements in addressing vascular permeability and cerebral edema after a stroke. This symposium aims to bridge the gap between research and clinical application, featuring leading experts in the field.

Significance of the CHARM and GAMES-RP Trials

According to Sven Jacobson, CEO of Remedy Pharmaceuticals, these analyses represent a significant opportunity to enhance treatment strategies for patients suffering from Large Hemispheric Infarction. With LHI affecting a considerable portion of the brain, successful management is crucial, particularly because patients often face debilitating outcomes from traditional treatments.

The GAMES-RP study involved 86 patients in a double-blind, randomized format assessing CIRARA's potential for LHI treatment. On the other hand, the CHARM trial included 535 participants, confirming CIRARA's potential in real-time clinical scenarios.

About CIRARA and Remedy Pharmaceuticals

CIRARA is designed for acute treatment, recognizing that time is critical for stroke patients. Remedy Pharmaceuticals, based in New York, is devoted to developing revolutionary treatments to improve outcomes in individuals affected by severe neurological conditions.

Conclusion

The data shared at ISC 2025 is anticipated to further strengthen the evidence supporting CIRARA's role in the treatment of Large Hemispheric Infarctions. It underscores Remedy Pharmaceuticals' commitment to advancing medical science and improving patient outcomes for those facing the life-altering impact of strokes.